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Abstract
Background: The CpG island methylator phenotype (CIMP) with widespread promoter
methylation is a distinct epigenetic phenotype in colorectal cancer, associated with microsatellite
instability-high (MSI-high) and BRAF  mutations. 18q loss of heterozygosity (LOH) commonly
present in colorectal cancer with chromosomal instability (CIN) is associated with global
hypomethylation in tumor cell. A recent study has shown an inverse correlation between CIN and
CIMP (determined by MINTs, p16, p14 and MLH1 methylation) in colorectal cancer. However, no
study has examined 18q LOH in relation to CIMP-high, CIMP-low (less extensive promoter
methylation) and CIMP-0 (CIMP-negative), determined by quantitative DNA methylation analysis.
Methods: Utilizing MethyLight technology (real-time PCR), we quantified DNA methylation in 8
CIMP-specific promoters {CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and
SOCS1} in 758 non-MSI-high colorectal cancers obtained from two large prospective cohorts. Using
four 18q microsatellite markers (D18S55, D18S56, D18S67 and D18S487) and stringent criteria for
18q LOH, we selected 374 tumors (236 LOH-positive tumors with ≥ 2 markers showing LOH; and
138 LOH-negative tumors with ≥ 3 informative markers and no LOH).
Results: CIMP-0 (0/8 methylated promoters) was significantly more common in 18q LOH-positive
tumors (59% = 139/236, p = 0.002) than 18q LOH-negative tumors (44% = 61/138), while CIMP-
low/high (1/8–8/8 methylated promoters) was significantly more common (56%) in 18q LOH-
negative tumors than 18q LOH-positive tumors (41%). These relations persisted after stratification
by sex, location, or the status of MSI, p53 expression (by immunohistochemistry), or KRAS/BRAF
mutation.
Conclusion: 18q LOH is correlated positively with CIMP-0 and inversely with CIMP-low and
CIMP-high. Our findings provide supporting evidence for relationship between CIMP-0 and 18q
LOH as well as a molecular difference between CIMP-0 and CIMP-low in colorectal cancer.
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Background
Chromosomal instability (CIN) appears to be a distinct
phenotype in colorectal cancer, and tumors with CIN
show frequent cytogenetic abnormalities and chromo-
somal gains and losses [1]. CIN is commonly assessed by
LOH analyses of microsatellite markers, and markers in
the 18q region appear to be generally more sensitive, com-
pared to markers in other chromosomal regions such as
1p, 2p, 3p, 5q, 8p and 17p [2-5]. The presence of 18q
LOH has been proposed as a worse prognostic marker for
patient survival in colorectal cancer [6-10], and appears to
predict resistance to fluorouracil-based chemotherapy
[11]. In particular, SMAD4 (DPC4), present in 18q21.1
and encoding a downstream signal transducer of TGF-β
(transforming growth factor-β), has been implicated as an
important tumor suppressor lost by 18q deletion [1,12].
Transcriptional inactivation by cytosine methylation at
promoter CpG islands of tumor suppressor genes is
thought to be an important mechanism in human car-
cinogenesis [13]. A number of tumor suppressor genes are
silenced by promoter methylation in colorectal cancer
[14]. Promoter CpG island methylation has been shown
to occur early in colorectal carcinogenesis [15]. A subset of
colorectal cancers exhibit promoter methylation in multi-
ple genes, referred to as the CpG island methylator pheno-
type (CIMP) [14,16]. CIMP-high colorectal tumors appear
to have a distinct clinical, pathologic and molecular pro-
file, including associations with female sex, proximal
tumor location, poor differentiation, microsatellite insta-
bility (MSI) and BRAF mutation [17-25]. In addition, we
have identified CIMP-low (with less widespread promoter
methylation) in colorectal cancer as a phenotype associ-
ated with male sex and KRAS mutations, different from
CIMP-high and CIMP-0 (CIMP-negative) [26]. We have
also shown a possible link between CIMP-low, MSI-low,
MGMT methylation/silencing and KRAS mutation, sup-
porting that CIMP-low tumors have unique molecular
features different from CIMP-high and CIMP-0 tumors
[27].
An association between global hypomethylation and 18q
LOH in colorectal cancer has been shown [4]. Genome-
wide DNA demethylation has been correlated with chro-
mosomal instability [28-30]. In ApcMin/+  mice, DNA
hypomethylation promotes microadenoma formation
through LOH at the Apc locus [31]. These studies exam-
ined genome-wide DNA methylation, but not DNA meth-
ylation in specific promoter CpG islands that is important
in silencing of individual tumor suppressor genes.
Recently, Goel et al. [32] has shown an inverse correlation
between CIN and CIMP in colorectal cancer, using
MINT1, MINT2, MINT31, p16, p14 and MLH1 methyla-
tion markers. However, no study has examined CIN in
relation to CIMP-high, CIMP-low and CIMP-0, utilizing
quantitative DNA methylation analysis on CIMP-specific
promoters recently described by Weisenberger et al. [24].
In this study, utilizing quantitative real-time PCR (Methy-
Light technology) on recently described CIMP-specific
promoters [23,24], and colorectal cancer samples from
two large prospective cohort studies, we examined rela-
tionship between 18q LOH and CIMP status in non-MSI-
H tumors. MethyLight assays can reproducibly distinguish
high from low levels of DNA methylation, the latter of
which likely have little or no biological significance [33].
We have been able to demonstrate differential relation-
ships of CIMP-low and CIMP-0 with 18q LOH.
Methods
Study group
For this study, we utilized the databases of two large pro-
spective cohort studies; the Nurses' Health Study (N =
121,700 women followed since 1976) [34], and the
Health Professional Follow-up Study (N = 51,500 men
followed since 1986) [35]. Informed consent was
obtained from all participants prior to inclusion in the
cohorts. A subset of the cohort participants developed
colorectal cancers during prospective follow-up. Thus,
these colorectal cancers represented population-based,
relatively unbiased samples (in contrast to retrospective or
single-hospital-based samples). Follow-up of these cohort
studies are still ongoing and outcomes data have not been
available yet. Previous studies on Nurses' Health Study
and Health Professionals Follow-up Study have described
baseline characteristics of cohort participants and incident
colorectal cancer cases, and confirmed that our colorectal
cancer cases were well representative as a population-
based sample [34,35]. We collected paraffin-embedded
tissue blocks from hospitals where cohort participants
with colorectal cancers had undergone resections of pri-
mary tumors. We excluded cases if adequate paraffin-
embedded tumor tissue was not available at the time of
this study. Among our cohort studies, there was no signif-
icant difference in demographic features between cases
with tissue available and those without available tissue
(Chan et al. in press). As a result, a total of 920 colorectal
cancer cases were initially included [36]. In only seven
other cases, MethyLight reactions failed (failure rate 7/927
= 0.76%). Among the 920 tumors, MSI status could be
determined in 889 tumors, and 131 tumors (15%) were
MSI-H, thus leaving 758 MSI-L/MSS tumors for further
analyses. For this study, we excluded MSI-H tumors
because of the presence of widespread unstable microsat-
ellites, and we selected cases only if strictly informative
results of 18q microsatellite status were available (see
below the method section for MSI and 18q LOH). As a
result, 374 colorectal cancer cases (174 from the men's
cohort and 200 from the women's cohort) were further
studied. Most cases have been previously characterized forBMC Cancer 2007, 7:72 http://www.biomedcentral.com/1471-2407/7/72
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status of CIMP, MSI, KRAS, and BRAF [23,26,36]. How-
ever, no tumor has previously been studied for 18q LOH
status in relation to MSI and CIMP. Tissue collection and
analyses were approved by the Institutional Review
Boards.
Genomic DNA extraction and whole genome 
amplification
Tumor and normal tissue was dissected from paraffin
embedded blocks and genomic DNA was extracted using
QIAmp DNA Mini Kit (Qiagen, Valencia, CA USA), as pre-
viously described [37]. Normal DNA was derived from a
resection margin or a random sampling of normal intes-
tine in a resected specimen. Whole genome amplification
of genomic DNA was performed by PCR using random
15-mer primers [37] for subsequent genetic analyses. Pre-
vious studies have shown that whole genome amplifica-
tion does not significantly affect subsequent
microsatellite analysis and gene sequencing [37,38].
Microsatellite instability (MSI) and 18q loss of 
heterozygosity (LOH)
Methods for MSI analysis were previously described [39].
In addition to D2S123, D5S346, D17S250, BAT25 and
BAT26 (the NCI panel), we used BAT40, D18S55,
D18S56, D18S67 and D18S487 (i.e., a 10-marker panel);
the latter four were located in 18q. "MSI-high (MSI-H)"
was defined as instability in 30% or more of the markers,
"MSI-low (MSI-L)" as instability in less than 30% of the
markers, and "microsatellite stability (MSS)" as no unsta-
ble marker.
For LOH analysis, we excluded MSI-H tumors because the
presence of unstable microsatellites made LOH analysis
difficult. We duplicated PCR reaction and electrophoresis
in each sample for D18S55, D18S56, D18S67 and
D18S487 to exclude allele dropouts of one of two alleles.
LOH at each locus (D18S55, D18S56, D18S67 or
D18S487) was defined as 40% or greater reduction of one
of two allele peaks in tumor DNA relative to normal DNA
[39]. In electropherograms, T1, T2, N1 and N2 were
defined as peak heights of allele 1 in tumor DNA, allele 2
in tumor DNA, allele 1 in normal DNA and allele 2 in nor-
mal DNA, respectively. LOH at each locus was positive
when (T1*N2)/(T2*N1) was ≤ 6/10 in two duplicated
runs, or ≥ 10/6 in two duplicated runs.
Overall 18q LOH positivity was strictly defined as the
presence of at least two informative markers with LOH,
and 18q LOH negativity as the presence of at least three
informative markers and no evidence of LOH. These strin-
gent criteria enabled us to select biologically homogenous
groups of tumors. When we used less stringent criteria in
which 18q LOH positivity was defined as ≥ 1 informative
markers with LOH and 18q LOH negativity as ≥ 2 (or ≥ 1)
informative markers and no evidence of LOH, the rela-
tions between 18q LOH and CIMP became weaker (data
not shown).
Real-time PCR (MethyLight) for quantitative DNA 
methylation analysis
Sodium bisulfite treatment on genomic DNA was per-
formed as previously described [33]. Real-time PCR to
measure DNA methylation (MethyLight) was performed
as previously described [40,41]. Utilizing ABI 7300
(Applied Biosystems, Foster City, CA USA) for quantita-
tive real-time PCR, we amplified 8 CIMP-specific promot-
ers, including CACNA1G, CDKN2A (p16), CRABP1, IGF2,
MLH1, NEUROG1, RUNX3 and SOCS1 [23,24]. COL2A1
(the collagen 2A1 gene) was used to normalize for the
amount of input bisulfite-converted DNA [33,41]. Prim-
ers and probes were previously described as follows:
CACNA1G, CRABP1 and  NEUROG1  [23,24],CDKN2A
and COL2A1 [41]; MLH1  [33]; and IGF2, RUNX3 and
SOCS1  [24]. The percentage of methylated reference
(PMR, i.e., degree of methylation) at each locus was calcu-
lated by dividing the GENE:COL2A1  ratio of template
amounts in a sample by the GENE:COL2A1 ratio of tem-
plate amounts in SssI-treated human genomic DNA (pre-
sumably fully methylated) and multiplying this value by
100 [40]. Methylation positivity in each locus was defined
as PMR > 4 (except for CRABP1 and IGF2 for which posi-
tivity was defined as PMR > 6) [23,33,41]. Precision and
performance characteristics of bisulfite conversion and
subsequent MethyLight assays have been previously eval-
uated and the assays have been validated [33].
The CpG island methylator phenotype-high (CIMP-high)
was defined as the presence of ≥ 6/8 methylated promot-
ers, CIMP-low as the presence of 1/8 to 5/8 methylated
promoters CIMP-0  as the absence (0/8) of methylated
promoters, based on the previous data that CIMP-high
and CIMP-low show high BRAF and KRAS mutation rates,
respectively [26,36].
Sequencing of KRAS and BRAF
Methods of KRAS and BRAF sequencing have been previ-
ously described [26,37]. Pyrosequecing was performed
using the PSQ96 HS System (Biotage AB and Biosystems,
Uppsala, Sweden).
Immunohistochemistry for p53
Methods of tissue microarray construction [42] and p53
immunohistochemistry have previously been described
[43]. p53 positivity was defined as 50% or more of tumor
cells with unequivocal strong nuclear staining. All immu-
nohistochemically-stained slides were interpreted by a
pathologist (S.O.) blinded from clinical and other labora-
tory data.BMC Cancer 2007, 7:72 http://www.biomedcentral.com/1471-2407/7/72
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Statistical analysis
In statistical analysis, chi-square test (or Fisher's exact test
when N < 10 in any category) was performed for categor-
ical data, using the SAS program (version 9.1, SAS Insti-
tute, Cary, NC). All p values were two-sided, and statistical
significance was set at p ≤ 0.05.
Results
CIMP-high, CIMP-low and CIMP-0 in non-MSI-H 
colorectal cancer
We obtained 920 colorectal cancer specimens and quanti-
fied DNA methylation in the 8 CIMP-specific gene pro-
moters (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1,
NEUROG1, RUNX3 and SOCS1) by MethyLight technol-
ogy. All of the 8 loci were selected, based on screening of
195 CpG island loci throughout the human genome
[23,24]. The use of the 8 markers as a CIMP diagnostic
panel has previously been validated, and all of the 8 mark-
ers are sensitive and specific markers for CIMP-high [36].
Among the 920 tumors, MSI status could be determined
in 889 tumors, and 758 tumors (85%) were determined
as MSI-L/MSS tumors for further analyses. A distribution
of MSI-L/MSS tumors according to the number of methyl-
ated markers is illustrated in Figure 1, which shows asso-
ciations between CIMP-high and BRAF  mutations,
between CIMP-low and KRAS  mutations, and between
CIMP-0 with wild-type BRAF/KRAS.
18q LOH and MSI status
For 18q LOH analysis, we analyzed four 18q microsatel-
lite markers (D18S55, D18S56, D18S67 and D18S487)
by duplicated PCR in MSI-L and MSS tumors. To select a
biologically homogenous group of tumors (without a
considerable number of misclassified tumors), we used
stringent criteria for 18q LOH positivity (i.e., the presence
of at least two informative markers showing LOH). 18q
LOH negativity was also strictly defined as the presence of
at least three informative markers and no evidence of
LOH. Among the 758 MSI-L/MSS tumors, 374 tumors
were classified as either 18q LOH positive (N = 236) or
negative (N = 138) by our stringent criteria. 18q LOH was
more common in MSI-L tumors (82% = 23/28, p = 0.05)
than in MSS tumors (62% = 213/346).
18q LOH and methylation in individual CpG islands
We examined the frequency of methylation in each
marker according to the 18q LOH status in the MSI-L/MSS
tumors (Table 1). The frequency of methylation in each
marker was consistently higher in LOH-negative tumors
than in LOH-positive tumors. However, no consistent
relationship between LOH and methylation in any of the
markers was present after tumors were stratified by the
CIMP status (data not shown).
18q LOH in MSI-L/MSS colorectal cancer is associated 
positively with CIMP-0 and inversely with CIMP-low/high
We assessed the frequency of 18q LOH in MSI-L/MSS
tumors in relation to the number of methylated promot-
ers (Figure 2). The frequency of 18q LOH was highest in
CIMP-0 tumors (with 0 methylated promoters), and
appeared to decline as the number of methylated promot-
ers increased. To assess relationship between 18q LOH
and CIMP, we examined the frequencies of CIMP-0 in 18q
LOH-positive tumors and 18q LOH-negative tumors
(Table 2). Among the 374 MSI-L/MSS tumors, CIMP-0
was significantly more common in 18q LOH-positive
tumors (59%, p = 0.002) than in 18q LOH-negative
tumors (44%). Even after tumors were stratified by MSI
status, 18q LOH-positive tumors consistently showed a
higher frequency of CIMP-0 than 18q LOH-negative
tumors.
Relationship between 18q LOH and CIMP-0 persists after 
various stratifications
To examine whether the relationship between 18q LOH
and CIMP status was affected by clinical or other molecu-
lar variables, we stratified tumors by sex, tumor location,
p53 status or KRAS/BRAF status, and examined the fre-
quencies of CIMP-0 in 18q LOH positive or negative
Distribution of MSI-L/MSS colorectal cancers according to  the number of methylated promoters Figure 1
Distribution of MSI-L/MSS colorectal cancers according to 
the number of methylated promoters. The X and Y axes indi-
cate the number of methylated promoters and the number of 
tumors, respectively. Based on the KRAS and BRAF mutation 
rates, CIMP-high is defined as the presence of ≥ 6/8 methyl-
ated promoters. Also note that CIMP-0 tumors with 0/8 
methylated promoters are more likely to have both wild-
type KRAS and BRAF, compared to CIMP-low tumors with 1/8 
to 5/8 methylated promoters. Abbreviations: BRAF+, BRAF-
mutated KRAS wild-type; KRAS+, KRAS-mutated BRAF wild-
type; K+/B+, KRAS-mutated BRAF-mutated; KRAS/BRAF WT, 
both wild-type KRAS and BRAF; MSI-L, microsatellite instabil-
ity-low; MSS, microsatellite stable.
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tumors (Table 3). Interestingly, 18q LOH positive tumors
consistently showed a higher frequency of CIMP-0 and a
lower frequency of CIMP-low/high than 18q LOH nega-
tive tumors in all of the 9 categories (male, female, right
colon, left colon, etc.; 11 categories including MSI-L and
MSS, p = 0.0005), further supporting the positive correla-
tion between 18q LOH and CIMP-0.
Frequency of 18q LOH in various MSI/CIMP subtypes of 
colorectal cancer
A molecular classification of colorectal cancer based on
MSI and CIMP status is increasingly important, because
MSI and CIMP status reflect global genomic and epige-
nomic aberrations, respectively. We evaluated the fre-
quency of 18q LOH in relation to combined MSI and
CIMP status (Figure 3). Either among MSI-L or MSS
tumors, CIMP-0 tumors showed a higher frequency of
18q LOH than CIMP-low and CIMP-high tumors.
Discussion
We conducted this study to examine 18q loss of heterozy-
gosity (LOH) in relation to the CpG island methylator
phenotype (CIMP) in colorectal cancer. Discovering
molecular correlates is important in cancer research,
because it may: (1) provide clues to pathogenesis; (2) pro-
pose or support the existence of a new molecular subtype;
(3) alert investigators to be aware of potential confound-
ing in association studies; and (4) suggest surrogate mark-
ers in clinical or research settings. In the current study, our
strict criteria for 18q LOH could select biologically more
homogenous groups of samples, enabling us to identify
interesting molecular correlates that might otherwise have
been obscured or missed. The use of quantitative DNA
methylation assays (MethyLight) on the 8 carefully-
selected CIMP-specific promoters [23,24] as well as popu-
lation-based samples of colorectal cancer from two large
prospective cohort studies [34,35] has enabled us to accu-
rately estimate the frequency of colorectal cancers with a
specific molecular feature (e.g., CIMP-0).
We have demonstrated that 18q LOH is correlated posi-
tively with CIMP-0 (with 0/8 methylated promoter) and
inversely with CIMP-low (1/8 to 5/8 methylated promot-
ers). Our data are somewhat in agreement with the data
by Goel et al. [32], who discovered an inverse correlation
between LOH and CIMP. However, there are differences
in methods and results between our study and Goel et al's
study [32] that warrant discussion. Although more LOH
markers were analyzed, Goel et al. [32] used non-quanti-
tative methylation-specific PCR (MSP) assays on MINT1,
MINT2, MINT31, p16 (CDKN2A), p14 (ARF), MLH1 (and
additional non-CIMP related markers). The authors
found only several CIMP-0 tumors (with no methylated
promoter), which were too small in number to conclude
a significant difference between CIMP-0 and CIMP-low.
In the current study, we could demonstrate the significant
difference between CIMP-low and CIMP-0 in MSI-L/MSS
tumors. There might be several reasons for the discrepan-
cies, including differences in the sample sizes, the methyl-
ation assays (MSP vs. MethyLight) and the methylation
markers (MINTs vs. CIMP-high-specific markers). The use
of MSP could overestimate the frequency of methylation
positivity in any marker. We have shown that low-level
CpG island methylation below the threshold of gene
silencing should be reproducibly distinguished from
high-level methylation by quantitative DNA methylation
analysis [33]. The methylation markers MINT1, MINT2
and MINT31 were originally described as the markers for
CIMP [16]. A recent extensive study by Weisenberger et al.
[24] has shown that MINT1, MINT2 and MINT31 are not
Frequency of 18q LOH in MSI-L/MSS colorectal cancers,  according to the number of methylated promoters Figure 2
Frequency of 18q LOH in MSI-L/MSS colorectal cancers, 
according to the number of methylated promoters. CIMP-0 
tumors (N = 200) with 0 methylated promoters show the 
highest frequency of 18q LOH.
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Table 1: Frequency of methylation in each marker according to 18q LOH status in MSI-L/MSS colorectal cancers
18q LOH status Total N No. of tumors with methylation in:
CACNA1G CDKN2A (p16) CRABP1 IGF2 MLH1 NEUROG1 RUNX3 SOCS1
LOH(+) 236 23 (9.7%) 55 (23%) 44 (19%) 28 (12%) 4 (1.7%) 44 (19%) 15 (6.4%) 15 (6.4%)
LOH(-) 138 26 (19%) 38 (28%) 47 (34%) 30 (22%) 3 (2.2%) 41 (30%) 23 (17%) 14 (10%)
Abbreviations: LOH, loss of heterozygosity; MSI-L, microsatellite instability-low; MSS, microsatellite stable.BMC Cancer 2007, 7:72 http://www.biomedcentral.com/1471-2407/7/72
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as specific for BRAF mutations as our markers, CACNA1G,
CDKN2A (p16), IGF2, MLH1, NEUROG1, RUNX3 and
SOCS1. By the use of the latter markers, we could separate
CIMP-high tumors (with frequent BRAF mutations) from
CIMP-low tumors (with frequent KRAS mutations) (Fig-
ure 1).
Our data provide supporting evidence for a molecular dif-
ference between CIMP-low and CIMP-0 (CIMP-negative)
in colorectal cancer. We have previously shown that
CIMP-low tumors are associated with male sex and KRAS
mutation, whereas CIMP-high tumors are associated with
female sex and BRAF mutation, and CIMP-0 tumors are
associated with wild-type KRAS/BRAF  oncogenes and
exhibits no sex predilection [26]. We have recently shown
that the relationship between MSI-low and MGMT meth-
ylation/silencing is present only in CIMP-low tumors, but
not in CIMP-high or CIMP-0 tumors, supporting unique
molecular features of CIMP-low different from CIMP-high
and CIMP-0 [27]. A significant difference in the BRAF
mutation frequencies between CIMP-high and CIMP-low
tumors has repeatedly been shown by other investigators
[20-22,24]; however, a difference between CIMP-low and
CIMP-0 has not been widely investigated. We admit that
the difference between CIMP-low and CIMP-0 is not as
clear-cut as that between CIMP-high and CIMP-low. Thus,
additional studies are necessary to identify a panel of
markers specific for CIMP-low to be clearly distinguished
from CIMP-0.
The relationship between global DNA methylation level
(but not specific CpG island methylation) and chromo-
somal aberrations has been studied. In a study using Apc-
Min/+  mice, Yamada et al. [31] have shown that
Table 3: Frequency of CIMP in MSI-L/MSS tumors with or without 18q LOH after various stratifications
18q LOH status Total N CIMP-0 (0/8)a CIMP-low/high (1/8 – 8/8)a P value CIMP-low (1/8 – 5/8) CIMP-high 
(6/8 – 8/8)
Men (+) 104 59 (57%) 45 (43%) 0.02 41 (39%) 4 (3.8%)
(-) 70 28 (40%) 42 (60%) 39 (56%) 3 (4.3%)
Women (+) 132 80 (61%) 52 (39%) 47 (36%) 5 (3.8%)
(-) 68 33 (49%) 35 (51%) 30 (44%) 5 (7.4%)
Right colon (+) 45 19 (42%) 26 (58%) 23 (51%) 3 (6.7%)
(-) 37 12 (32%) 25 (68%) 21 (57%) 4 (11%)
Left colon (+) 87 54 (62%) 33 (38%) 32 (36%) 1 (1.9%)
(-) 34 16 (47%) 18 (53%) 18 (53%) 0
p53(+)^ (+) 122 73 (60%) 49 (40%) 48 (39%) 1 (0.8%)
(-) 43 19 (44%) 24 (56%) 22 (51%) 2 (4.7%)
p53(-)^ (+) 113 66 (58%) 47 (42%) 0.03 39 (35%) 8 (7.1%)
(-) 90 39 (43%) 51 (57%) 45 (50%) 6 (6.7%)
KRAS(-) BRAF(-) (+) 142 93 (65%) 49 (35%) 47 (33%) 2 (1.4%)
(-) 51 30 (59%) 21 (41%) 21 (41%) 0
KRAS(+) BRAF(-) (+) 71 39 (55%) 32 (45%) 31 (44%) 1 (1.4%)
(-) 72 30 (42%) 42 (58%) 39 (54%) 3 (4.2%)
KRAS(-) BRAF(+) (+) 17 3 (18%) 14 (82%) 8 (47%) 6 (35%)
(-) 12 0 12 (100%) 7 (58%) 5 (42%)
The frequency of CIMP-0 is consistently higher in 18q LOH(+) tumors than in 18q LOH(-) tumors among the 9 different categories (men, women, 
right colon, etc.; 11 categories including MSI-L and MSS, p = 0.0005).
Footnote: a Fraction of the number of methylated promoters. ^ p53 status was assessed by immunohistochemistry.
CIMP, CpG island methylator phenotype; LOH, loss of heterozygosity; MSI-L, microsatellite instability-low; MSS, microsatellite stable.
Table 2: Frequencies of CIMP-0 and CIMP-low/high in MSI-L/MSS colorectal cancer with or without 18q LOH
18q LOH status Total N CIMP-0 (0/8)a CIMP-low/high (1/8 – 8/8)a P value CIMP-low (1/8 – 5/8)a CIMP-high (6/8 – 8/8)a
All cases 920 431 (47%) 489 (53%) 353 (38%) 136 (15%)
MSI-L/MSS (+) 236 139 (59%) 97 (41%) 0.002 88 (37%) 9 (3.8%)
(-) 138 61 (44%) 77 (56%) 69 (50%) 8 (5.8%)
MSI-L (+) 23 15 (65%) 8 (35%) 6 (26%) 2 (8.7%)
(-) 5 1 (20%) 4 (80%) 3 (60%) 1 (20%)
MSS (+) 213 124 (58%) 89 (42%) 0.01 82 (38%) 7 (3.3%)
(-) 133 60 (45%) 73 (55%) 66 (50%) 7 (5.3%)
a Fraction of the number of methylated promoters.
CIMP, CpG island methylator phenotype; LOH, loss of heterozygosity; MSI-L, microsatellite instability-low; MSS, microsatellite stable.BMC Cancer 2007, 7:72 http://www.biomedcentral.com/1471-2407/7/72
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hypomorphic alleles of the Dnmt1  gene cause DNA
hypomethylation in intestinal cells leading to increased
microadenoma formation through LOH at the Apc locus,
suggesting a pathogenetic link between DNA hypometh-
ylation and LOH. Genome-wide DNA demethylation has
been correlated with chromosomal instability and
genomic copy number changes [28,29]. Genetic disrup-
tion of DNA methyltransferase or treatment with 5-aza-
deoxycytidine results in chromosomal translocations or
rearrangements [30,44]. Matsuzaki et al. [4] have exam-
ined global DNA methylation levels in colorectal cancer
by examining long interspersed nucleotide elements
(LINE), and correlated methylation data with the status of
MSI and LOH at 5q, 8p, 17p and 18q. The authors showed
that the presence of LOH was correlated with global
hypomethylation in colorectal cancer, and that the associ-
ation between 18q LOH and global hypomethylation was
particularly strong compared to the associations between
the other LOH markers and global hypomethylation [4].
Thus, 18q LOH appeared to be a good predictor for global
hypomethylation. Interestingly, our current study has
shown that 18q LOH is correlated with CIMP-0 (i.e., no
methylation in the 8 CIMP-specific CpG islands).
Together with the data by Matsuzaki et al. [4], there may
be a possibility that a global methylation level may posi-
tively correlate with DNA hypermethylation at specific
CpG islands (i.e., CIMP status). Matsuzaki et al. [4] have
also shown that MSI-H tumors exhibit a higher global
methylation level than MSS tumors though they have not
examined MLH1 promoter methylation. These data also
support the positive correlation between a global methyl-
ation level and specific promoter CpG island methylation,
because MLH1 promoter methylation is the most com-
mon cause for sporadic MSI-H tumors and also very spe-
cific marker for CIMP-high [23].
Conclusion
We have demonstrated that 18q LOH in non-MSI-H
colorectal cancer is correlated positively with CIMP-0, and
inversely with CIMP-low and CIMP-high. Our data pro-
vide additional evidence to support a biological difference
between CIMP-0 and CIMP-low in colorectal cancer. Our
findings of the link between LOH and CIMP-0 indicate
that potential confounding effects of CIMP status need to
be considered when one examines relationship between
allelic imbalance (or chromosomal instability) and
patient outcomes or any other clinical or molecular varia-
bles. Additional studies will shed lights on the possible
pathogenetic link between CIMP-0 and chromosomal
instability in colorectal cancer.
Abbreviations and HUGO Gene Nomenclature 
Committee (HGNC)-approved official gene 
symbols used
CACNA1G, calcium channel, voltage-dependent, T type
alpha-1G subunit
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cancer. CIMP-0 tumors show higher frequencies of 18q LOH 
than CIMP-low and CIMP-high tumors within the MSI-L and 
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phenotype; LOH, loss of heterozygosity; MSI-L, microsatel-
lite instability-low; MSS, microsatellite stable.
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